Nefrologia
Hemoperfusão | Aspectos técnicos e estado de arte.
23 Mai, 2022 | 13:15hHemoperfusion: technical aspects and state of the art – Critical Care
Resultados de 2 casos de transplante renal suíno-para-humano.
20 Mai, 2022 | 14:13hResults of Two Cases of Pig-to-Human Kidney Xenotransplantation – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Genetically modified pig kidney xenografts were transplanted into two brain-dead human recipients. The xenografts functioned immediately, showed no evidence of acute rejection over a period of 54 hours. https://t.co/gWlpX1dCTC pic.twitter.com/Zp5XdA4QH5
— NEJM (@NEJM) May 18, 2022
Prescrição de inibidores de SGLT2 em pacientes com doença renal crônica: indicações em expansão e considerações práticas.
20 Mai, 2022 | 13:56h
Comentário no Twitter
Prescribing #SGLT2 Inhibitors in Patients with #CKD : Expanding Indications and Practical Considerations
👍🏻 This interesting article discusses about practical considerations of #SGLT2i from #nephrology point of view https://t.co/Wq2plAqbhq @Nephro_Sparks @NephJC @kidney_boy pic.twitter.com/eHmpOHso86
— Henry Han, MBBS, MD (@HanCardiomd) May 17, 2022
Sob licença de CC BY-NC-ND 4.0
Tratamento da hipertensão estágio 1: considerar os riscos, interromper a progressão.
20 Mai, 2022 | 13:28hEstudo randomizado | Efeito da metilprednisolona oral no declínio da função renal em pacientes com nefropatia por IgA.
19 Mai, 2022 | 13:18hEffect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Oral Glucocorticoids for IgA Nephropathy – JAMA
Comentário: Multi-country study provides a clear treatment option for IgA nephropathy – News Medical
Diretrizes | Tratamento de infecções recorrentes de trato urinário em mulheres.
19 Mai, 2022 | 13:07hPatogênese, diagnóstico e tratamento da alcalose metabólica.
12 Mai, 2022 | 14:46h
Comentário no Twitter
Metabolic Alkalosis Pathogenesis, Diagnosis, and Treatment: Core Curriculum 2022https://t.co/5ujfpBDwBz (FREE) pic.twitter.com/e1RvYVAzC8
— AJKD (@AJKDonline) May 8, 2022
Estudo randomizado | Reloxaliase vs. placebo na hiperoxalúria entérica.
10 Mai, 2022 | 14:14hRandomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria – NEJM Evidence
Comentário no Twitter
Patients with enteric hyperoxaluria received reloxaliase, an enzyme that degrades oxalate in the GI tract, or placebo with food for 4 weeks. There was a greater reduction in urinary oxalate excretion with reloxaliase. https://t.co/x7m12QHyWX#NephTwitter #UroSoMe #ClinicalTrials pic.twitter.com/rzCpd6YfLM
— NEJM Evidence (@NEJMEvidence) May 6, 2022
Estudo randomizado | Eficácia e segurança da difelikefalina em pacientes com prurido moderado a grave recebendo hemodiálise.
10 Mai, 2022 | 14:09h
Comentário no Twitter
This RCT found difelikefalin, a κ-opioid receptor agonist, improved moderate to severe pruritus in Japanese hemodialysis patients. Difelikefalin is expected to be a new option for the treatment of uremic pruritus in patients with end stage kidney disease. https://t.co/cXqNx4QIaS pic.twitter.com/7QdA9GoLwN
— JAMA Network Open (@JAMANetworkOpen) May 5, 2022